Comparative Pharmacology
Head-to-head clinical analysis: CYCLESSA versus PROCOMP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLESSA versus PROCOMP.
CYCLESSA vs PROCOMP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.
The combination of acetaminophen, caffeine, and isometheptene exerts its effects through multiple mechanisms: acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and pain; caffeine is a non-selective adenosine receptor antagonist that enhances pain relief; isometheptene is a sympathomimetic amine that constricts dilated cerebral blood vessels.
One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
50 mg orally once daily
None Documented
None Documented
Desogestrel: 38±13 hours (terminal); ethinyl estradiol: 14±3 hours (terminal). Steady-state reached after 7-10 days.
Terminal elimination half-life: 12-18 hours (mean 15 hours). Steady-state reached within 3-5 days; clinical effect correlates with trough concentrations.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); enterohepatic circulation.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; total recovery ~90% in urine and feces within 72 hours.
Category C
Category C
Oral Contraceptive
Oral Contraceptive